APP
SRPT icon

Alpha Paradigm Partners’s Sarepta Therapeutics SRPT Stock Holding History

Alpha Paradigm Partners’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,888
Closed -$430K – 597
2022
Q3 		$430K Buy
+3,888
New +$392K 0.19% 185

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alpha Paradigm Partners's SRPT Position: Q4 2022 in Review

Alpha Paradigm Partners sold out of Sarepta Therapeutics (SRPT) in Q4 2022, closing a stake of 3,888 shares — an estimated $430K sold.

Alpha Paradigm Partners first reported a position in SRPT in Q3 2022 and held it in 1 quarter. The position peaked at $430K in Q3 2022. 411 funds tracked by Wall St. Rank hold SRPT as of Q4 2022.

  • Alpha Paradigm Partners reported no remaining Sarepta Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Alpha Paradigm Partners sold 3,888 Sarepta Therapeutics shares in Q4 2022, an estimated $430K.
  • Alpha Paradigm Partners first reported a position in Sarepta Therapeutics in Q3 2022 and held it in 1 quarter.
  • Alpha Paradigm Partners's Sarepta Therapeutics position peaked at $430K in Q3 2022.
  • 411 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2022.

Based on Alpha Paradigm Partners's 13F filing for Q4 2022, filed 13 Feb 2023.